Applications

1648 – OncoSil™ for locally advanced unresectable pancreatic cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status -
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome -

Application details

Reason for application

New/amendment to MBS item.

Service or technology in this application

OncoSil™ is a device that imparts a pre-determined dose of beta radiation directly into cancerous pancreatic tissue. The beta particles emitted by OncoSil™ travel a short distance in tissue causing damage to cancer cell DNA, which renders them incapable of further cell division and proliferation. OncoSil in combination with Gemcitabine or FOLFIRINOX is considered to be a better treatment option for locally advanced unresectable pancreatic cancer.

There are three proposed medical services:

Nuclear Medicine

  • Professional attendance and handling for assessment and preparation of OncoSil™ microparticles for injection of by endoscopic ultrasound (endoscopy with ultrasound imaging).
  • Single-photon emission computed tomography Scan on Day 1 and Day 7 post OncoSil implantation

Endoscopy

  • Injection of OncoSil™ by endoscopic ultrasound (endoscopy with ultrasound imaging)

Type: Therapeutic

Medical condition this application addresses

Pancreatic cancer occurs when the malignant (cancerous) cells multiplies in the tissues of the gland. It often begins within the cells of pancreatic ducts, and subsequently spreading to the rest of the gland and surrounding regions. The cancer that begins in the ducts of pancreas affecting exocrine cells are called pancreatic adenocarcinoma or pancreatic exocrine cancer. Approximately 70% of the pancreatic cancer arises in the head of the pancreas. Rarely, the cancer initiates in the neuroendocrine cells of pancreas, called the islet cell carcinoma or pancreatic endocrine cancer.

Based on the spread and severity of the disease, pancreatic cancers can be grouped into resectable, borderline resectable, Locally advanced, and metastatic stages.

Meetings to consider this application

  • PASC meeting: 10 to 11 December 2020
  • ESC meeting: -
  • MSAC meeting: -